Biotec Pharmacon presentation at Carnegie small and mid cap seminar

9/6/2012 4:53 AM EST

CEO Svein W. F. Lien gave a presentation of Biotec Pharmacon at Carnegie
small and mid cap seminar. The presentation was held 5. September 2012
in Stockholm. Please find the presentation attached.
About Biotec Pharmacon:

Biotec Pharmacon is a biopharmaceutical company that develops and
manufactures new immunomodulatory products and cold adapted marine
enzymes. The wholly owned Biotec BetaGlucans AS focuses on identifying,
developing and commercializing innovative products to meet unmet medical
needs in wound treatment, cancer and gastroenterology. The company's
technology is protected by a large patent portfolio covering amongst
others applications of yeast beta glucans as adjuvants in conjunction
with monoclonal antibodies. The subsidiary ArcticZymes AS aspires to
become a leading supplier of novel enzymes for diagnostics and genetic
research. More information on www.biotec.no.

Statement under the Private Securities Litigation Reform Act:

With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements
that involve risk and uncertainties that may individually or mutually
impact the matters herein described, including but not limited to,
product acceptance, the ability to continually obtained increased orders
of its products, the ability to meet installation goals, economic,
competitive, governmental impacts, whether pending patents will be
granted or defendable, validity of intellectual property and patents,
the ability to license patents, the ability to commercialize
developmental products, as well as technological and/or other factors.